Document Detail


The 5-lipoxygenase-activating protein inhibitor, GSK2190915, attenuates the early and late responses to inhaled allergen in mild asthma.
MedLine Citation:
PMID:  23331559     Owner:  NLM     Status:  In-Data-Review    
Abstract/OtherAbstract:
BACKGROUND: GSK2190915, a potent 5-lipoxygenase-activating protein inhibitor, prevents the synthesis of leukotrienes and 5-oxo-6,8,11,14-eicosatetraenoic acid (5-oxo-ETE).
OBJECTIVE: To assess the effect of GSK2190915 on the allergen-induced asthmatic responses.
METHODS: Nineteen eligible male subjects with mild asthma were enrolled in and completed this four-centre, double-blind, two-way crossover study (ClinicalTrials.gov NCT00748306). Subjects took GSK2190915 100 mg and placebo orally once daily for 5 days in randomized order. On Day 1 and 4 they had a methacholine challenge, on Day 3 they had an inhaled allergen challenge, and on Days 4 and 6 they had sputum induction.
RESULTS: GSK2190915 attenuated the early (0-2 h) and late (4-10 h) asthmatic responses to inhaled allergen compared with placebo. There was a statistically significant attenuation of the early asthmatic response (EAR) by GSK2190915; treatment difference of GSK2190915 vs. placebo for the minimum FEV(1) EAR was 0.408 L (0.205, 0.611). There was a statistically significant attenuation of the late asthmatic response (LAR) by GSK2190915; the treatment difference of GSK2190915 vs. placebo for the minimum FEV(1) LAR was 0.229 L (0.041, 0.417). There was a statistically significant attenuation of allergen-induced sputum eosinophil count on Day 4 following GSK2190915: mean treatment difference (95% CI) between GSK2190915 and placebo was -9.95% (-18.15%, -1.77%). Compared with placebo, GSK2190915 100 mg reduced median sputum LTB(4) by > 90% on Days 4 and 6. There was no effect on methacholine PC(20) post allergen. GSK2190915 was generally well tolerated.
CONCLUSION AND CLINICAL RELEVANCE: GSK2190915 shows potential as a treatment for patients with asthma.
Authors:
S E Kent; M Boyce; Z Diamant; D Singh; B J O'Connor; P S Saggu; V Norris
Related Documents :
24274219 - Characterizing rhinitis subtypes.
21036509 - Adapting problem-solving therapy for depressed older adults in methadone maintenance tr...
3310529 - Restricted environmental stimulation therapy of smoking: a parametric study.
15876899 - A double-blind placebo-controlled trial of bupropion sustained-release for smoking cess...
12804419 - Alpha2 adrenergic agonists for the management of opioid withdrawal.
17999769 - The mental status of 1090 heroin addicts at entry into treatment: should depression be ...
8306739 - The effect of exogenous surfactant therapy on lung function following cardiopulmonary b...
19628959 - Cognitive therapy versus rogerian supportive therapy in borderline personality disorder...
20553629 - An evaluation of the hypolipidemic effect of an extract of hibiscus sabdariffa leaves i...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology     Volume:  43     ISSN:  1365-2222     ISO Abbreviation:  Clin. Exp. Allergy     Publication Date:  2013 Feb 
Date Detail:
Created Date:  2013-01-21     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8906443     Medline TA:  Clin Exp Allergy     Country:  England    
Other Details:
Languages:  eng     Pagination:  177-86     Citation Subset:  IM    
Copyright Information:
© 2012 Blackwell Publishing Ltd.
Affiliation:
GlaxoSmithKline, London, United Kingdom.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Mechanisms of tolerance induction in allergic disease: integrating current and emerging concepts.
Next Document:  Segmental allergen challenge enhances chitinase activity and levels of CCL18 in mild atopic asthma.